Authors: Ngatali CFS, Moukassa D, Nkoua-Mbon JB.
Objective: The objective of our study was to determine chemotherapy and these frequent side effects of breast cancer in Pointe-Noire.
Patients and Methods: This was a retrospective descriptive study that took place in the cancerology and internal medicine department during the period from January 1, 2019 to December 31, 2021. Were included in our study: patients with and histological diagnosis, and having received at least one course of chemotherapy and having presented hematological toxicity: anemia and/or neutropenia. Patients having status performances less than 2. The variables studied were: Age, level of study, stage of extension, type of chemotherapy, type of toxicity. L4ANA The khi2 was used and results were statistically significant for a value of P<5%.
Results: The average age of the patients was 50.35 ± 13.6 years. The extremes were 27 years and 79 years old. The most represented age group was the age group from 37 to 46 years with 18 cases or 33.33%. The most represented level study in our study was the primary level 70%, followed by secondary level 26% and the upper or superior level 11%. Metastatic stage of location was represented in 16.6% of cases, the local stage was represented in 16.7% of cases. The most commonly chemotherapy used was FAC protocol in 50% of cases, followed by FAC+DOCETAXEL in 47% of cases, AC protocol was used in 3% of cases The majority of patients had received more than 3 courses of chemotherapy in 83% of cases case. Frequent toxicities were fatigue 100%, alopecia 100%, nausea 100%, hematological 95%, vomiting 20%. The most used chemotherapy was FAC type chemotherapy in 19 cases, 4 cases, 2 cases respectively at the locoregional, metastatic and local stages.
Conclusion: Chemotherapy for breast cancers in our context with limited resources is of the anrhracyclines (AC, FAC) and taxanes (docetaxel) type. These chemotherapies are responsible for haematological toxicities, fatigue, nausea, vomiting and alopecia.
View/Download pdf